|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
ES2139598T3
(es)
|
1990-07-10 |
2000-02-16 |
Medical Res Council |
Procedimientos para la produccion de miembros de parejas de union especifica.
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
ES2246502T3
(es)
|
1990-08-29 |
2006-02-16 |
Genpharm International, Inc. |
Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
|
|
JP3540315B2
(ja)
|
1991-09-23 |
2004-07-07 |
メディカル リサーチ カウンシル |
キメラ抗体の製造−組合せアプローチ
|
|
PT1024191E
(pt)
|
1991-12-02 |
2008-12-22 |
Medical Res Council |
Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
|
|
JPH07503132A
(ja)
|
1991-12-17 |
1995-04-06 |
ジェンファーム インターナショナル,インコーポレイティド |
異種抗体を産生することができるトランスジェニック非ヒト動物
|
|
EP0656941B1
(en)
|
1992-03-24 |
2005-06-01 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
|
ES2301158T3
(es)
|
1992-07-24 |
2008-06-16 |
Amgen Fremont Inc. |
Produccion de anticuerpos xenogenicos.
|
|
AU6819494A
(en)
|
1993-04-26 |
1994-11-21 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
GB9313509D0
(en)
|
1993-06-30 |
1993-08-11 |
Medical Res Council |
Chemisynthetic libraries
|
|
FR2707189B1
(fr)
|
1993-07-09 |
1995-10-13 |
Gradient Ass |
Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé.
|
|
CA2177367A1
(en)
|
1993-12-03 |
1995-06-08 |
Andrew David Griffiths |
Recombinant binding proteins and peptides
|
|
ATE340590T1
(de)
|
1994-07-13 |
2006-10-15 |
Chugai Pharmaceutical Co Ltd |
Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
|
|
CA2219361C
(en)
|
1995-04-27 |
2012-02-28 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
WO1996034096A1
(en)
|
1995-04-28 |
1996-10-31 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
EP1332209B1
(en)
|
2000-09-08 |
2009-11-11 |
Universität Zürich |
Collections of repeat proteins comprising repeat modules
|
|
CA2418835A1
(en)
|
2000-10-16 |
2002-04-25 |
Phylos, Inc. |
Protein scaffolds for antibody mimics and other binding proteins
|
|
US20030157561A1
(en)
|
2001-11-19 |
2003-08-21 |
Kolkman Joost A. |
Combinatorial libraries of monomer domains
|
|
EP1411118B1
(en)
|
2001-06-22 |
2008-09-03 |
Chugai Seiyaku Kabushiki Kaisha |
Cell proliferation inhibitors containing anti-glypican-3 antibody
|
|
WO2003029462A1
(en)
|
2001-09-27 |
2003-04-10 |
Pieris Proteolab Ag |
Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
|
|
US7402427B2
(en)
|
2002-04-30 |
2008-07-22 |
Dnavec Research Inc. |
Vectors with modified protease-dependent tropism
|
|
AU2003242024A1
(en)
|
2002-06-05 |
2003-12-22 |
Chugai Seiyaku Kabushiki Kaisha |
Method of constructing antibody
|
|
WO2004021861A2
(en)
|
2002-09-03 |
2004-03-18 |
Vit Lauermann |
Targeted release
|
|
AU2002328429A1
(en)
|
2002-09-04 |
2004-03-29 |
Chugai Seiyaku Kabushiki Kaisha |
CONSTRUCTION OF ANTIBODY USING MRL/lpr MOUSE
|
|
CA2543360A1
(en)
|
2003-10-24 |
2005-05-06 |
Joost A. Kolkman |
Ldl receptor class a and egf domain monomers and multimers
|
|
JP2005168328A
(ja)
|
2003-12-08 |
2005-06-30 |
Hokkaido Univ |
シグナル伝達活性を有する細胞質蛋白質の活性制御方法
|
|
DK2383295T3
(en)
|
2003-12-10 |
2015-06-15 |
Squibb & Sons Llc |
Ip-10 antibodies and uses thereof
|
|
WO2005110453A2
(en)
|
2004-04-12 |
2005-11-24 |
Catalyst Biosciences, Inc. |
Cleavage of vegf and vegf receptor by wildtype and mutant mt-sp1
|
|
AU2005256113B2
(en)
|
2004-07-09 |
2011-02-10 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-glypican 3 antibody
|
|
CA2591813A1
(en)
|
2004-12-21 |
2006-06-29 |
Centocor, Inc. |
Anti-il-12 antibodies, epitopes, compositions, methods and uses
|
|
EP3530736A3
(en)
|
2005-05-09 |
2019-11-06 |
ONO Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
|
WO2007027935A2
(en)
|
2005-08-31 |
2007-03-08 |
The Regents Of The University Of California |
Cellular libraries of peptide sequences (clips) and methods of using the same
|
|
CA2632866A1
(en)
|
2005-12-01 |
2007-06-07 |
Domantis Limited |
Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
|
|
JP2009517069A
(ja)
|
2005-12-01 |
2009-04-30 |
ドマンティス リミテッド |
インターロイキン1受容体1型に結合する競合ドメイン抗体フォーマット
|
|
TWI417301B
(zh)
|
2006-02-21 |
2013-12-01 |
Wyeth Corp |
對抗人類介白素-22(il-22)之抗體及其用途
|
|
ES2372709T3
(es)
|
2006-07-05 |
2012-01-25 |
Catalyst Biosciences, Inc. |
Procedimientos de cribado de proteasas y proteasas identificadas por los mismos.
|
|
WO2008016854A2
(en)
|
2006-08-02 |
2008-02-07 |
The Uab Research Foundation |
Methods and compositions related to soluble monoclonal variable lymphocyte receptors of defined antigen specificity
|
|
JP2010500876A
(ja)
|
2006-08-18 |
2010-01-14 |
アブリンクス エン.ヴェー. |
Il−6媒介性シグナル伝達に関連する疾患及び障害の治療のための、il−6rに指向性を有するアミノ酸配列及びこれを含むポリペプチド
|
|
CA2678626A1
(en)
|
2007-02-28 |
2008-09-04 |
Novimmune S.A. |
Anti-ip-10 antibodies and methods of use thereof
|
|
CA2688434A1
(en)
|
2007-06-06 |
2008-12-11 |
Domantis Limited |
Polypeptides, antibody variable domains and antagonists
|
|
EP2158221B1
(en)
|
2007-06-21 |
2018-08-29 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
|
CA2696263C
(en)
|
2007-08-15 |
2017-06-13 |
Bing Liu |
Monospecific and multispecific antibodies and method of use
|
|
AU2016213702C1
(en)
|
2007-08-22 |
2018-11-29 |
Cytomx Therapeutics, Inc. |
Activatable binding polypeptides and methods of identification and use thereof
|
|
EP2190861A4
(en)
|
2007-08-22 |
2011-03-30 |
Univ California |
ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
|
|
EP3543256A1
(en)
|
2009-01-12 |
2019-09-25 |
Cytomx Therapeutics Inc. |
Modified antibody compositions, methods of making and using thereof
|
|
MX2011010681A
(es)
|
2009-04-10 |
2012-01-20 |
Ablynx Nv |
Secuencias mejoradas de aminoacidos dirigidas contra il-6r y polipeptidos que comprenden el mismo para el tratamiento de enfermedades y trastornos relacionados con il-6r.
|
|
JP2011026294A
(ja)
|
2009-06-26 |
2011-02-10 |
Canon Inc |
化合物
|
|
RU2583876C2
(ru)
|
2009-08-17 |
2016-05-10 |
Роше Гликарт Аг |
Иммуноконъюгаты направленного действия
|
|
US8734774B2
(en)
|
2010-04-02 |
2014-05-27 |
University Of Rochester |
Protease activated cytokines
|
|
US9193791B2
(en)
|
2010-08-03 |
2015-11-24 |
City Of Hope |
Development of masked therapeutic antibodies to limit off-target effects
|
|
BR112013002167A2
(pt)
*
|
2010-08-24 |
2016-05-31 |
Roche Glycart Ag |
anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação
|
|
WO2012028697A1
(en)
|
2010-09-01 |
2012-03-08 |
Eth Zürich, Institute Of Molecular Biology And Biophysics |
Affinity purification system based on donor strand complementation
|
|
WO2012123755A1
(en)
|
2011-03-17 |
2012-09-20 |
The University Of Birmingham |
Re-directed immunotherapy
|
|
JP6400470B2
(ja)
|
2011-05-16 |
2018-10-03 |
ジェネロン(シャンハイ)コーポレイション リミテッド |
多重特異性Fab融合タンパク質および使用法
|
|
TW201817745A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之FcRn結合域的治療性抗原結合分子
|
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
|
WO2013148248A1
(en)
|
2012-03-30 |
2013-10-03 |
Bayer Healthcare Llc |
Protease-regulated antibodies
|
|
NZ629675A
(en)
|
2012-04-06 |
2017-02-24 |
Omeros Corp |
Compositions and methods of inhibiting masp-1, masp-2 and/or masp-3 for treatment of paroxysmal nocturnal hemoglobinuria
|
|
WO2013176730A1
(en)
|
2012-05-22 |
2013-11-28 |
Life Technologies As |
Recombinant antibody compositions and methods of use thereof
|
|
SG11201408554QA
(en)
|
2012-06-22 |
2015-02-27 |
Cytomx Therapeutics Inc |
Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
|
|
US9487590B2
(en)
|
2012-09-25 |
2016-11-08 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
|
|
EP2957633A4
(en)
|
2013-02-15 |
2016-08-17 |
Nat Univ Corp Kyoto Inst Tech |
METHOD OF RESTRICTING AN ANTIBODY, METHOD FOR THE PRODUCTION OF A RECONSTITUTED ANTIBODY, RECONSTITUTED ANTIBODIES AND USES THEREOF
|
|
KR20250051130A
(ko)
|
2013-09-25 |
2025-04-16 |
싸이톰스 테라퓨틱스, 인크. |
매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법
|
|
US9540440B2
(en)
|
2013-10-30 |
2017-01-10 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
|
|
WO2015089283A1
(en)
|
2013-12-11 |
2015-06-18 |
Cytomx Therapeutics, Inc. |
Antibodies that bind activatable antibodies and methods of use thereof
|
|
EP3628328B1
(en)
|
2014-01-31 |
2022-09-14 |
Cytomx Therapeutics Inc. |
Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
|
|
BR112016016658A2
(pt)
|
2014-02-06 |
2018-01-23 |
F. Hoffmann-La Roche Ag |
proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão
|
|
CA2955947A1
(en)
|
2014-07-25 |
2016-01-28 |
Cytomx Therapeutics, Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
|
GB201413357D0
(en)
|
2014-07-28 |
2014-09-10 |
Philogen Spa |
Antibodies for treatment and diagnosis
|
|
EP3197916A2
(en)
|
2014-09-25 |
2017-08-02 |
Amgen Inc. |
Protease-activatable bispecific proteins
|
|
WO2016077505A2
(en)
|
2014-11-11 |
2016-05-19 |
Amunix Operating Inc. |
Targeted xten conjugate compositions and methods of making same
|
|
IL300408B2
(en)
|
2015-01-20 |
2025-11-01 |
Cytomx Therapeutics Inc |
Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof
|
|
MA42971A
(fr)
|
2015-03-13 |
2018-08-15 |
Cytomx Therapeutics Inc |
Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
|
|
EP3778640A1
(en)
|
2015-05-01 |
2021-02-17 |
Genentech, Inc. |
Masked anti-cd3 antibodies and methods of use
|
|
AU2016258988A1
(en)
|
2015-05-04 |
2017-12-07 |
Cytomx Therapeutics, Inc |
Anti-ITGa3 antibodies, activatable anti-ITGa3 antibodies, and methods of use thereof
|
|
TWI787796B
(zh)
|
2015-05-04 |
2022-12-21 |
美商Cytomx生物製藥公司 |
抗cd71抗體類、可活化之抗cd71抗體類及使用彼等之方法
|
|
BR112017023872A2
(pt)
|
2015-05-04 |
2018-07-24 |
Cytomx Therapeutics Inc |
anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
|
|
JP6841754B2
(ja)
|
2015-05-13 |
2021-03-10 |
中外製薬株式会社 |
多重抗原結合分子融合体、医薬組成物、線状エピトープの同定方法、および多重抗原結合分子融合体の製造方法
|
|
WO2017025698A1
(en)
|
2015-08-11 |
2017-02-16 |
Queen Mary University Of London |
Bispecific, cleavable antibodies
|
|
WO2017162587A1
(en)
|
2016-03-22 |
2017-09-28 |
F. Hoffmann-La Roche Ag |
Protease-activated t cell bispecific molecules
|
|
KR102379464B1
(ko)
|
2016-06-20 |
2022-03-29 |
키맵 리미티드 |
항-pd-l1 항체
|
|
CN110072890B
(zh)
|
2016-11-03 |
2022-11-29 |
百时美施贵宝公司 |
可活化的抗ctla-4抗体及其用途
|
|
CA3041279A1
(en)
|
2016-11-28 |
2018-05-31 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding domain, and polypeptide including conveying section
|
|
AU2017364818C1
(en)
|
2016-11-28 |
2025-05-15 |
Chugai Seiyaku Kabushiki Kaisha |
Ligand-binding molecule having adjustable ligand binding activity
|
|
CA3046432A1
(en)
|
2016-12-13 |
2018-06-21 |
Astellas Pharma Inc. |
Anti-human cd73 antibody
|
|
CN118085076A
(zh)
|
2017-06-02 |
2024-05-28 |
埃博灵克斯股份有限公司 |
结合聚集蛋白聚糖的免疫球蛋白
|
|
IL270951B2
(en)
|
2017-06-02 |
2025-05-01 |
Merck Patent Gmbh |
ADAMTS5, MMP13 and aggrecan-binding polypeptides
|
|
US20200306301A1
(en)
|
2017-07-03 |
2020-10-01 |
Torque Therapeutics, Inc. |
Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof
|
|
US20190038935A1
(en)
|
2017-08-07 |
2019-02-07 |
Timofey Ignatyev |
Exercise game and apparatus employing color-changing base locations
|
|
CN107602706B
(zh)
|
2017-10-16 |
2020-12-04 |
湖北大学 |
一种切割效率增强的hrv 3c蛋白酶底物突变体及其应用
|
|
KR20200089312A
(ko)
|
2017-11-28 |
2020-07-24 |
추가이 세이야쿠 가부시키가이샤 |
리간드 결합 활성을 조정 가능한 리간드 결합 분자
|
|
KR20250134208A
(ko)
|
2017-11-28 |
2025-09-09 |
추가이 세이야쿠 가부시키가이샤 |
항원 결합 도메인 및 운반 부분을 포함하는 폴리펩티드
|
|
KR102020131B1
(ko)
|
2017-12-29 |
2019-09-09 |
박성원 |
광경화성 조성물 및 이를 이용하여 제조된 성형품
|
|
CA3115461A1
(en)
|
2018-03-09 |
2019-09-12 |
AskGene Pharma, Inc. |
Novel cytokine prodrugs
|
|
MX2020012251A
(es)
|
2018-05-14 |
2021-04-28 |
Werewolf Therapeutics Inc |
Polipeptidos de interleucina-2 activables y metodos de uso de los mismos.
|
|
WO2019222296A1
(en)
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable interleukin 12 polypeptides and methods of use thereof
|
|
JP7428661B2
(ja)
|
2018-05-30 |
2024-02-06 |
中外製薬株式会社 |
Il-1r1結合ドメインおよび運搬部分を含むポリペプチド
|
|
EP3807312A4
(en)
|
2018-05-30 |
2022-07-20 |
Chugai Seiyaku Kabushiki Kaisha |
POLYPEPTIDE WITH AGGRECAN-BINDING DOMAIN AND A CARRIER UNIT
|
|
EP3816182A4
(en)
|
2018-05-30 |
2022-07-13 |
Chugai Seiyaku Kabushiki Kaisha |
LIGAND BINDING MOLECULE WITH SINGLE DOMAIN ANTIBODY
|
|
US20210355219A1
(en)
|
2018-09-21 |
2021-11-18 |
Harpoon Therapeutics, Inc. |
Conditionally activated target-binding molecules
|
|
CN113286812B
(zh)
|
2018-09-27 |
2025-05-30 |
西里欧发展公司 |
掩蔽型细胞因子多肽
|
|
KR102884523B1
(ko)
|
2018-10-03 |
2025-11-10 |
젠코어 인코포레이티드 |
IL-12 이종이량체 Fc-융합 단백질
|
|
EP3981428A4
(en)
|
2019-06-05 |
2023-07-12 |
Chugai Seiyaku Kabushiki Kaisha |
Protease substrate, and polypeptide including protease cleavage sequence
|
|
CN113905757B
(zh)
|
2019-06-05 |
2026-01-13 |
中外制药株式会社 |
抗体切割位点结合分子
|
|
AU2020316002B2
(en)
|
2019-07-25 |
2026-05-07 |
The University Of Chicago |
Compositions and methods comprising protease-activated therapeutic agents
|
|
CN115943210A
(zh)
|
2020-01-20 |
2023-04-07 |
中外制药株式会社 |
配体结合融合蛋白
|
|
KR20240035556A
(ko)
|
2021-07-19 |
2024-03-15 |
추가이 세이야쿠 가부시키가이샤 |
융합 폴리펩타이드를 이용하는 프로테아제 매개성의 표적 특이적 사이토카인 송달
|